Cases & Deals

  • Home
  • Practices
  • Viveris Management and Amundi Private Equity Funds grant exclusive acquisition option to Actelion for Trophos acquisition

Share

Viveris Management and Amundi Private Equity Funds grant exclusive acquisition option to Actelion for Trophos acquisition

July 2010

Client(s) Viveris Management and Amundi Private Equity Funds

Jones Day advised Viveris Management and Amundi Private Equity Funds, shareholders of Trophos SA, a clinical stage pharmaceutical company, in connection with the €10 million (US$12.9 million) exclusive acquisition option granted to Actelion Ltd. for a final acquisition price between €125 million (US$162 million) and €195 million (US$253 million) in cash, contingent upon various regulatory approvals and other clinical progress.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.